Expression of Somatostatin Receptor Subtypes in Human Thyroid Tumors: the Immunohistochemical and Molecular Biology (RT-PCR) Investigation

Overview

Journal Thyroid Res

Specialty Endocrinology

Date 2009 Jan 29

PMID 19173713

Citations 19

Authors

Hanna Pisarek

Tomasz Stepien

Robert Kubiak

Edyta Borkowska

Marek Pawlikowski

Affiliations

Soon will be listed here.

Abstract

Human endocrine tumors often express the somatostatin receptors SSTR 1-5 with different intensity. It has been widely investigated their distribution in pituitary adenomas, brain tumors, adrenal tumors and neuroendocrine tumors in gastrointestinal tract (NET). Some of studies also concern the expression of SSTRs in thyroid tumors but they are mainly limited to parafollicular C cells - derived medullary thyroid carcinomas (MTC). Results of SSTR 1-5 detection in other thyroid pathologies like follicular adenomas and papillary cancers are still scarce and often controversial, depending of investigation method used. The aim of this study was to report the presence of all the 5 subtypes of SSTR (including 2A and 2B SSTR isoforms) in some surgically treated human thyroid tumors by means of immunohistochemistry and real-time PCR method and to correlate the results obtained with both techniques. SSTR 1 protein was expressed in 88.8% of investigated cases, SSTR 2A and 2B both in 44.4%, SSTR 3 in 55.5%, SSTR 4 in 11.2% and SSTR 5 in 33.3%. SSTR 1 is the dominant form in the thyroid gland tumor and hyperplasia. We found positive confirmation of both methods in 88.8% for SSTR 1, 2A, 3 subtypes, in 22.2% for SSTR 4 and in 100% for SSTR 5. It suggests that somatostatin multiligand analogs or selective SSTR 1 agonists may be used in thyroid tumors treatment.

Citing Articles

Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer.

Volpe F, Nappi C, Zampella E, Di Donna E, Maurea S, Cuocolo A Curr Oncol. 2024; 31(7):3870-3884.

PMID: 39057158 PMC: 11276085. DOI: 10.3390/curroncol31070286.

Somatostatin receptor imaging of thyroid tissue and differentiated thyroid cancer using gallium-68-labeled radiotracers-a review of clinical studies.

Pishdad R, Treglia G, Mehta A, Santhanam P Endocrine. 2024; 85(2):566-575.

PMID: 38498126 DOI: 10.1007/s12020-024-03779-3.

Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Czajkowski M, Kaemmerer D, Sanger J, Sauter G, Wirtz R, Schulz S BMC Cancer. 2022; 22(1):740.

PMID: 35799158 PMC: 9261050. DOI: 10.1186/s12885-022-09839-z.

Comparative distribution of somatostatin and somatostatin receptors in PTU-induced hypothyroidism.

Singh S, Somvanshi R, Panda V, Kumar U Endocrine. 2020; 70(1):92-106.

PMID: 32335798 DOI: 10.1007/s12020-020-02309-1.

Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Mu Z, Zhang X, Lin Y Chonnam Med J. 2019; 55(3):127-135.

PMID: 31598469 PMC: 6769251. DOI: 10.4068/cmj.2019.55.3.127.

References

Pawlikowski M, Pisarek H, Kunert-Radek J, Radek A . Immunohistochemical detection of somatostatin receptor subtypes in "clinically nonfunctioning" pituitary adenomas. Endocr Pathol. 2003; 14(3):231-8. DOI: 10.1007/s12022-003-0015-1. View

Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, Weise W . Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res. 1998; 4(9):2047-52. View

Patel Y, Greenwood M, Kent G, Panetta R, Srikant C . Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun. 1993; 192(1):288-94. DOI: 10.1006/bbrc.1993.1412. View

de Sa S, Correa-Giannella M, Machado M, de Souza J, Pereira M, Patzina R . Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer. 2006; 13(1):69-78. DOI: 10.1677/erc.1.00962. View

Mato E, Matias-Guiu X, Chico A, Webb S, Cabezas R, Berna L . Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1998; 83(7):2417-20. DOI: 10.1210/jcem.83.7.4955. View

Ain K, Taylor K, Tofiq S, Venkataraman G . Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1997; 82(6):1857-62. DOI: 10.1210/jcem.82.6.4013. View

Pawlikowski M . [The incidence of somatostatin receptors in human neoplasms in the light of ex vivo-in vitro studies]. Endokrynol Pol. 2006; 57(3):238-43. View

Zatelli M, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C . Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab. 2006; 91(6):2218-24. DOI: 10.1210/jc.2006-0334. View

Pisarek H, Stepien T, Kubiak R, Pawlikowski M . Somatostatin receptors in human adrenal gland tumors--immunohistochemical study. Folia Histochem Cytobiol. 2008; 46(3):345-51. DOI: 10.2478/v10042-008-0051-2. View

10.

Druckenthaner M, Schwarzer C, Ensinger C, Gabriel M, Prommegger R, Riccabona G . Evidence for Somatostatin receptor 2 in thyroid tissue. Regul Pept. 2006; 138(1):32-9. DOI: 10.1016/j.regpep.2006.08.005. View

11.

Reubi J, Chayvialle J, Franc B, Cohen R, Calmettes C, Modigliani E . Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991; 64(4):567-73. View

12.

Reisine T, Bell G . Molecular biology of somatostatin receptors. Endocr Rev. 1995; 16(4):427-42. DOI: 10.1210/edrv-16-4-427. View

13.

Atkinson H, England J, Rafferty A, Jesudason V, Bedford K, Karsai L . Somatostatin receptor expression in thyroid disease. Int J Exp Pathol. 2013; 94(3):226-9. PMC: 3664968. DOI: 10.1111/iep.12024. View

14.

de Herder W, Hofland L, Lely A, Lamberts S . Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2004; 10(4):451-8. DOI: 10.1677/erc.0.0100451. View

15.

Ferone D, Pivonello R, van Hagen P, Dalm V, Lichtenauer-Kaligis E, Waaijers M . Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab. 2002; 283(5):E1056-66. DOI: 10.1152/ajpendo.00205.2001. View

16.

Tisell L, Ahlman H, Wangberg B, Kolby L, Fjalling M, Forssell-Aronsson E . Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid. Br J Cancer. 1999; 79(9-10):1579-82. PMC: 2362738. DOI: 10.1038/sj.bjc.6690251. View

17.

Hoyer D, Bell G, Berelowitz M, Epelbaum J, Feniuk W, Humphrey P . Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995; 16(3):86-8. DOI: 10.1016/s0165-6147(00)88988-9. View

18.

Nilsson O, Bejegard S, Kolby L, Bernhardt P, Molne J, Hashemi S . 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000; 41(4):636-42. View

19.

Patel Y . Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest. 1997; 20(6):348-67. DOI: 10.1007/BF03350317. View